The obstructive sleep apnoea diagnosis pathway in Australian sleep medicine practice has continued to evolve through 2024 and into 2026. Three factors have shaped the changes — the role of home sleep testing has expanded, the wait times for in-laboratory polysomnography have remained meaningful at most sleep services, and the digital health workflows around sleep diagnosis have matured.

Where the diagnosis pathway sits in May 2026:

Referral. Primary care referrals to sleep medicine continue to be the dominant entry point. The use of validated symptom screening tools — Epworth Sleepiness Scale, STOP-Bang, and the Berlin Questionnaire — in primary care is now routine. Patients presenting with characteristic symptoms and elevated screening scores are typically referred for sleep study within 4–8 weeks at most sleep services.

Home sleep apnoea testing. Type 3 home sleep apnoea testing is now the most common first investigation for uncomplicated suspected OSA in most Australian sleep services. The clinical pathway has matured to use HSAT as the first-line investigation for patients with high pre-test probability, intact cognitive and motor function for device application, and no significant comorbidity that would benefit from in-laboratory study.

In-laboratory polysomnography. In-laboratory PSG remains the standard investigation for complex cases — central sleep apnoea suspicion, significant comorbidity, paediatric sleep studies, REM-related conditions, parasomnias, and patients where HSAT has been inconclusive or where therapy decisions are sensitive to the additional data that PSG provides. Wait times for in-laboratory PSG remain meaningful at most public services and at peak periods at most private services.

Diagnostic reporting. The reporting standards on sleep studies have continued to align across major Australian sleep services. The American Academy of Sleep Medicine scoring criteria remain the international reference and Australian sleep services are reporting against them with broadly consistent practice.

What is working better in 2026:

Triage from referral to investigation. The use of pre-investigation screening data — symptom scores, comorbidity status, BAC characteristics — to triage referred patients to HSAT versus PSG has reduced unnecessary in-laboratory studies for many uncomplicated cases. The patients who benefit from in-laboratory PSG are getting it, and the patients who do not need it are reaching diagnosis faster through HSAT.

Therapy initiation. The pathway from positive diagnosis to therapy initiation has tightened at most sleep services. The mask fitting, the device titration, and the early adherence support are typically completed within 2–4 weeks of the diagnostic study at most well-organised services.

Telehealth review. Telehealth follow-up after therapy initiation is now routine. The data download from CPAP devices is reviewed remotely and clinical review can be conducted by telehealth for stable patients. This has improved access and reduced clinic occupancy for routine follow-up.

What remains challenging:

In-laboratory PSG wait times. The wait time for an in-laboratory PSG remains meaningful at most services. Patients who require in-laboratory study are typically waiting longer than is clinically ideal for diagnosis.

Paediatric sleep studies. The paediatric sleep medicine service capacity in Australia remains constrained relative to demand. Paediatric in-laboratory PSG wait times are typically longer than adult wait times and the demand has been growing through 2024–25.

Complex sleep disorders. Patients with complex presentations — central sleep apnoea, sleep-related hypoventilation, parasomnias, REM behaviour disorder — continue to need in-laboratory studies and the diagnostic complexity is meaningful. The specialist sleep physician capacity for complex cases is the rate limiter on these pathways.

Therapy adherence. CPAP adherence at the population level remains below the clinical ideal. The work of supporting adherence in the first 90 days continues to be where the difference between successful and unsuccessful long-term therapy is made.

Operational notes for primary care and sleep services in mid-2026:

Pre-test probability matters. Patients with high pre-test probability of OSA, no complicating factors, and clear symptom presentation are well-served by HSAT as the first investigation. Patients with lower pre-test probability or complicating factors are better served by in-laboratory PSG. The triage decision affects both diagnostic accuracy and time-to-diagnosis.

Documentation of comorbidity. The referral letter that includes documented comorbidity, current medications, and previous investigations significantly speeds the sleep service triage and patient pathway planning.

Patient preparation. The patients who are well-prepared for the sleep study — informed about the device, familiar with the device night-prior instructions, comfortable with the technology — have higher first-attempt diagnostic study success rates.

Mandibular advancement therapy. For mild to moderate OSA in patients who are not CPAP-tolerant, mandibular advancement therapy through dental sleep medicine is an established alternative and the integration between sleep medicine and dental sleep medicine has continued to improve. Patients who are CPAP-intolerant should be considered for MAT review.

For Australian primary care practitioners and sleep service operators in mid-2026, the working read is that the OSA diagnosis pathway is functioning well for uncomplicated cases through HSAT-led triage, that in-laboratory PSG remains essential for complex cases but with capacity constraints, and that the work of supporting therapy adherence through the first 90 days is where the long-term clinical outcome is most influenced.

The next 12 months will likely bring continued expansion of HSAT capacity, continued telehealth integration into the follow-up workflow, and continued attention to the in-laboratory PSG wait time at most services. The pathway is broadly in good shape and the operational improvements continue.